GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » Market Cap

Aratana Therapeutics (Aratana Therapeutics) Market Cap : $241.09 Mil (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aratana Therapeutics's share price for the quarter that ended in Mar. 2019 was $3.6. Aratana Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2019 was 48.35 Mil. Therefore, Aratana Therapeutics's market cap for the quarter that ended in Mar. 2019 was $174.05 Mil.

Aratana Therapeutics's quarterly market cap increased from Sep. 2018 ($280.21 Mil) to Dec. 2018 ($294.54 Mil) but then declined from Dec. 2018 ($294.54 Mil) to Mar. 2019 ($174.05 Mil).

Aratana Therapeutics's annual market cap declined from Dec. 2016 ($262.84 Mil) to Dec. 2017 ($223.72 Mil) but then increased from Dec. 2017 ($223.72 Mil) to Dec. 2018 ($294.54 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aratana Therapeutics's Enterprise Value for Today is $241.09 Mil.


Aratana Therapeutics Market Cap Historical Data

The historical data trend for Aratana Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aratana Therapeutics Market Cap Chart

Aratana Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Market Cap
Get a 7-Day Free Trial 608.52 192.87 262.84 223.72 294.54

Aratana Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.01 199.47 280.21 294.54 174.05

Competitive Comparison of Aratana Therapeutics's Market Cap

For the Biotechnology subindustry, Aratana Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aratana Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Aratana Therapeutics's Market Cap falls into.



Aratana Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Aratana Therapeutics's Market Cap for the fiscal year that ended in Dec. 2018 is calculated as

Market Cap (A: Dec. 2018 )=Share Price (A: Dec. 2018 )*Shares Outstanding (EOP) (A: Dec. 2018 )
=$6.13*48.0489
=$294.54

Aratana Therapeutics's Market Cap for the quarter that ended in Mar. 2019 is calculated as

Market Cap (Q: Mar. 2019 )=Share Price (Q: Mar. 2019 )*Shares Outstanding (EOP) (Q: Mar. 2019 )
=$3.6*48.3473
=$174.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aratana Therapeutics  (NAS:PETX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Aratana Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Aratana Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Aratana Therapeutics (Aratana Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211
Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.
Executives
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Vort John Vander director C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson director 470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno director
David L Brinkley director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr director SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman director, officer: President and CEO
Peter Steven St director, officer: PRESIDENT AND CEO MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211